Matthew Brier is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Neurology Multiple Sclerosis, 7th Fl
Saint Louis, MO 631101032
Telephone
314-362-3293Registry record last updated 15 Apr 2025.
Clinical trials
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20258 payments$11,652openpaymentsdata.cms.gov ↗
- TG Therapeutics, Inc.Program year202513 payments
- Amgen Inc.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
50.2%Gabapentinoids21.9%Gabapentin100%Part D≥12 patientsSNRI11.2%Duloxetine Hcl100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
30.7%CD20-directed Cytolytic Antibody10.8%Kesimpta Pen100%Part D<11 patientsInterleukin inhibitors10%Enspryng100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
10%gamma-Aminobutyric Acid-ergic Agonist10%Baclofen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- PET and MRI Evaluation of Cerebral Inflammation and Metabolic Stress in Relapsing Multiple Sclerosis
Washington University
FY2026$231,872K23NS128325 - PET and MRI Evaluation of Cerebral Inflammation and Metabolic Stress in Relapsing Multiple Sclerosis
Washington University
FY2025$232,410K23NS128325 - PET and MRI Evaluation of Cerebral Inflammation and Metabolic Stress in Relapsing Multiple Sclerosis
Washington University
FY2024$232,918K23NS128325
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”